Prime Medicine to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Prime Medicine (Nasdaq: PRME), a biotechnology company focused on curative genetic therapies, has announced its participation in two upcoming investor conferences in September 2025:

The company will present at Citi's 2025 Biopharma Back to School Conference on September 2 at 4:45 p.m. ET in Boston, and at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8 at 1:05 p.m. ET in New York. Live webcasts will be available on Prime Medicine's website, with replays accessible for 90 days after each event.

CAMBRIDGE, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that company management will participate in the following upcoming conferences:

• Citi’s 2025 Biopharma Back to School Conference: Fireside chat on Tuesday, September 2, 2025, at 4:45 p.m. ET in Boston, MA.
• Morgan Stanley 23^rd Annual Global Healthcare Conference: Fireside chat on Monday, September 8, 2025, at 1:05 p.m. ET in New York, NY.

Live audio webcasts of each presentation will be available under “Events & Presentations” in the News & Events section of the Company’s website at www.primemedicine.com. Replays of each webcast will be available on the Prime Medicine website for 90 days following the event.

About Prime Medicine

Prime Medicine is a leading biotechnology company dedicated to creating and delivering the next generation of gene editing therapies to patients. The Company is deploying its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated one-time curative genetic therapies. Designed to make only the right edit at the right position within a gene while minimizing unwanted DNA modifications, Prime Editors have the potential to repair almost all types of genetic mutations and work in many different tissues, organs and cell types. Taken together, Prime Editing’s versatile gene editing capabilities could unlock opportunities across thousands of potential indications.

Prime Medicine is currently progressing a diversified portfolio of investigational therapeutic programs organized around our core areas of focus: liver, lung, and immunology and oncology. Across each core area, Prime Medicine is focused initially on a set of high value programs, each targeting a disease with well-understood biology and a clearly defined clinical development and regulatory path, and each expected to provide the foundation for expansion into additional opportunities. Over time, the Company intends to maximize Prime Editing’s broad and versatile therapeutic potential, as well as the modularity of the Prime Editing platform, to rapidly and efficiently expand beyond the diseases in its current pipeline, potentially including additional genetic diseases, immunological diseases, cancers, infectious diseases, and targeting genetic risk factors in common diseases, which collectively impact millions of people. For more information, please visit www.primemedicine.com.

© 2025 Prime Medicine, Inc. All rights reserved. PRIME MEDICINE, the Prime Medicine logos, and PASSIGE are trademarks of Prime Medicine, Inc. All other trademarks referred to herein are the property of their respective owners.

Investor and Media Contacts

Gregory Dearborn
Prime Medicine
857-209-0696
gdearborn@primemedicine.com 

Hannah Deresiewicz
Precision AQ
212-362-1200
hannah.deresiewicz@precisionaq.com

FAQ

When is Prime Medicine (PRME) presenting at the Citi Biopharma Conference 2025?

Prime Medicine will present at Citi's Biopharma Back to School Conference on Tuesday, September 2, 2025, at 4:45 p.m. ET in Boston, MA.

When is Prime Medicine's presentation at the Morgan Stanley Healthcare Conference 2025?

Prime Medicine will present at the Morgan Stanley Global Healthcare Conference on Monday, September 8, 2025, at 1:05 p.m. ET in New York, NY.

How can investors access Prime Medicine's conference presentations?

Investors can access live webcasts of the presentations in the Events & Presentations section of Prime Medicine's website (www.primemedicine.com). Replays will be available for 90 days following each event.

What type of company is Prime Medicine (PRME)?

Prime Medicine is a biotechnology company focused on developing a new class of differentiated one-time curative genetic therapies.